Viking Therapeutics, Inc (VKTX) stock analysis and AI prediction
The company facts of Viking Therapeutics, Inc, with its price and AI prediction for the next 10 market days in SharePreds.
Keep looking in SharePreds
You have looked at today's stocks on this website. SharePreds shows every stock's likelihood of rising, its chart and how its earlier predictions ended, with alerts on the ones you follow.
See all five apps
About Viking Therapeutics, Inc
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Sector
- Healthcare
- Exchange
- NASDAQ
- Market value
- $3.5 billion
- Size
- Mid cap
- Employees
- 74
- Headquarters
- SAN DIEGO, CA
- Listed since
- April 29, 2015
- Website
- vikingtherapeutics.com
More Healthcare stocks
Other mid cap stocks
Keep going
VKTX questions
What is the AI prediction for VKTX stock?
Each market day our model rates Viking Therapeutics, Inc (VKTX) Bullish, Neutral or Bearish for the next 10 market days. Predictions are indicative: they rest on price and volume data, and they can be wrong.
How often is the VKTX prediction updated?
Each market day, Monday to Friday, except market holidays. The date of the prediction is shown beside it.
What do Bullish, Neutral and Bearish mean?
Bullish means the model sees a rise as likely over the next 10 market days, Bearish a fall, and Neutral no clear direction.
Where can I see the exact likelihood for VKTX?
In the SharePreds app for iPhone and Android, with the stock's chart, alerts on it and how its earlier predictions ended.
Where can I see VKTX options?
The VKTX options page opens its calls and puts, with price, volume, implied volatility and the Greeks.